首页
beat365中国唯一官方网站
公司简介
技术平台
公司荣誉
发展历程
管理团队
产品中心
心血管介入
外周血管介入
神经介入
非血管介入
下载专区
新闻资讯
公司新闻
行业资讯
学术论文
加入我们
公司环境
员工发展
招聘岗位
联系我们
联系方式
在线留言
EN
A bioresorbable everolimus-eluting scaff old versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II)...
Background Despite rapid dissemination of an everolimus-eluting bioresorbable scaffold for treatment for coronary artery disease, no data from comparisons with its metallic stent counterpart are available. In a randomised controlled trial we aimed to compare an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent. Here we report secondary clinical and procedural outcomes after 1 year of follow-up.
2016
08-12
Evaluation of the Biodegradable Peripheral Igaki-Tamai Stent in the Treatment
This study sought to evaluate the safety and performance of the Igaki-Tamai (Igaki Medical Planning Company, Kyoto, Janpan) biodegradable stent in patients with occlusive superficial femoral artery (SFA) disease.
新型钴铬合金可降解涂层西罗莫司洗脱支架在猪冠状动脉过度扩张模型中对新生内膜的影响
评价L-605 钴铬合金支架平台、聚丙交酯- 乙交酯(PLGA)共聚物载体西罗莫司药物洗脱支架在小型猪冠状动脉过度扩张模型中的安全性和有效性。
Stent thrombosis with drug-eluting stents: is the paradigm shifting?
First-generation drug-eluting stents (DES), which impart the controlled release of sirolimus or paclitaxel from durable polymers to the vessel wall, have been consistently shown to reduce the risk of restenosis and target vessel revascularization compared with bare metal stents (BMS).
Nine-month angiographic and two-year clinical follow-up of polymer-free sirolimus-eluting stent versus durable-polymer sirolimus-eluting stent for coronary artery disease: the Nano randomized trial
First generation drug-eluting stents (DES) were associated with a high incidence of late stent thrombosis (ST), mainly due to delayed healing and re-endothelization by the durable polymer coating. This study sought to assess the safety and efficacy of the Nano polymer-free sirolimus-eluting stent (SES) in the treatment of patients with de novo coronary artery lesions.
Real world clinical performance of the zotarolimus eluting coronary stent system in Chinese patients: a prospective, multicenter registry study
Early clinical trials with the Endeavor zotarolimus eluting stent (ZES) in western populations demonstrated low rates of target lesion revascularization with a favorable safety profile including low late stent thrombosis with up to 5 years of follow-up. The aim of this clinical registry study was to evaluate real world clinical performance of the ZES coronary system in Chinese patients.
Six-month outcomes of the XINSORB bioresorbable sirolimus-eluting scaffold in treating single de novo lesions in human coronary artery
We aimed to investigate short-term outcomes of the XINSOEB bioresorbable sirolimus-eluting scaffold in human coronary artery.
科学家称五年内将3D打印人类心脏
美国科学家表示，未来几年之内将3D打印组装完整的心脏组织，并能与患者身体完美地结合在一起。
06-24
beat365中国唯一官方网站专家委员会成立
五月的北京，惠风和畅，春意盎然，鲜花怒放。在这美好的季节里，美国工程院院士、美国科学医学院院士和美国发明家学院院士、美国Rice大学的Antonios G. Mikos教授专程从美国休斯敦飞到北京，与其他几位专家一起从beat365中国唯一官方网站董事长刘青博士手中接过专家聘书，至此，一支由国内外顶尖专家组成的beat365中国唯一官方网站医疗器械有限公司专家委员会正式宣告成立。在随后召开的第一届beat365中国唯一官方网站专家委员会上， Mikos教授对公司研发的3D血管支架精密制造专利技术给予了高度评价。
06-01
中国心脏支架产业发展报告
增速之所以放缓主要归于三个缘由：一是高值耗材招标带来了降价风潮;二是由于患者多涌向三级医院，因此三级医院手术量基本饱和，目前基本处于平衡小幅增长的阶段;三则是广大县级地区受限于当地的医疗资源限制和新农合报销比例，增长缓慢。
2015
08-27
